Amyloid precursor protein mediates a tyrosine kinase-dependent activation response in endothelial cells.
Amyloid precursor protein mediates a tyrosine kinase-dependent activation response in endothelial cells.
复制标题
DOI:
10.1523/jneurosci.3107-09.2009
复制
发表时间:
2009-11-18
期刊:
影响因子:
--
通讯作者:
Combs CK
中科院分区:
文献类型:
--
作者:
Austin SA;Sens MA;Combs CK
Amyloid precursor protein (APP) is a ubiquitously expressed type one integral membrane protein. It has the ability to bind numerous extracellular matrix components and propagate signaling responses via its cytoplasmic phosphotyrosine, 682YENPTY687, binding motif. We recently demonstrated increased protein levels of APP, phosphorylated APP (Tyr682), and beta-amyloid (Aβ) in brain vasculature of atherosclerotic and Alzheimer’s disease (AD) tissue co-localizing primarily within the endothelial layer. This study demonstrates similar APP changes in peripheral vasculature from human and mouse apoE−/− aorta suggesting APP-related changes are not restricted to brain vasculature. Therefore, primary mouse aortic endothelial cells (PAEC) and human umbilical vein endothelial cells (HUVEC) were used as a model system to examine the function of APP in endothelial cells. APP multimerization with an anti-N-terminal APP antibody, 22C11, to simulate ligand binding stimulated a Src kinase family dependent increase in protein phosphotyrosine levels, APP phosphorylation, and Aβ secretion. Furthermore, APP multimerization stimulated increased protein levels of the proinflammatory proteins, cyclooxygenase (COX)-2 and vascular cell adhesion molecule (VCAM)-1 also in a Src kinase family dependent fashion. Endothelial APP was also involved in mediating monocytic cell adhesion. Collectively, these data demonstrate that endothelial APP regulates immune cell adhesion and stimulates a tyrosine kinase-dependent response driving acquisition of a reactive endothelial phenotype. These APP-mediated events may serve as therapeutic targets for intervention in progressive vascular changes common to cerebrovascular disease and AD.